Publications by authors named "Timon Bogumil"

Claim this Profile
I
Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.
Sven Schippling, Paul O'Connor, Volker Knappertz, Christoph Pohl, Timon Bogumil

J Neurol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of disease activity in 857 patients with MS treated with interferon beta-1b.
Hans-Peter Hartung, Ludwig Kappos, Douglas S Goodin, Paul O'Connor, Massimo Filippi, Timon Bogumil

J Neurol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.
Frank G Holz, Ramin Tadayoni, Stephen Beatty, Alan Berger, Matteo G Cereda, Timon Bogumil

Br J Ophthalmol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin 17F level and interferon β response in patients with multiple sclerosis.
Hans-Peter Hartung, Lawrence Steinman, Douglas S Goodin, Giancarlo Comi, Stuart Cook, Timon Bogumil

JAMA Neurol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study.
Christian Lampl, Stefan Nagl, Barry Arnason, Giancarlo Comi, Paul O Connor, Timon Bogumil

J Neurol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies.
Hans-Peter Hartung, Bernd Kieseier, Douglas S Goodin, Barry Gw Arnason, Giancarlo Comi, Timon Bogumil

J Neuroinflammation· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.
Douglas S Goodin, Hans-Peter Hartung, Paul O'Connor, Massimo Filippi, Barry Arnason, Timon Bogumil

Mult Scler· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
Paul O'Connor, Massimo Filippi, Barry Arnason, Giancarlo Comi, Stuart Cook, Timon Bogumil

Lancet Neurol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Barrie J Hurwitz, Douglas Jeffery, Barry Arnason, Kim Bigley, Patricia Coyle, Timon Bogumil

Clin Ther· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b.
Andreas Bitsch, Alexander Dressel, Kathrin Meier, Timon Bogumil, Florian Deisenhammer

J Neurol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis.
Maryna Yushchenko, Michael Mäder, Ercan Elitok, Andreas Bitsch, Alexander Dressel, Timon Bogumil

J Neurol· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon-beta-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patients.
Dirk Bahner, Christine Klucke, Bernd Kitze, Ercan Elitok, Timon Bogumil

Neurosci Lett· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis